Compounds > ferrous succinate
Page last updated: 2024-11-11

ferrous succinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ferrous succinate: RN given refers to Fe(+2)(1:1) salt; important as iron supplement [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10464762
SCHEMBL ID275423
MeSH IDM0079657

Synonyms (22)

Synonym
iron succinate
ferplex (tn)
ferrous succinate
10030-90-7
D08015
818zyk7n91 ,
einecs 233-082-3
butanedioic acid, iron(2+) salt (1:1)
unii-818zyk7n91
iron(ii) succinate
ferrlecit 2
iron succinate (fe(o4c4h4))
ferrous succinate [mi]
succinic acid, iron(2+) salt (1:1)
ferrous succinate [mart.]
ferrous succinate [who-dd]
ferromyn
SCHEMBL275423
succinic acid iron(ii) salt;succinic acid iron(ii) salt
DB14489
butanedioate;iron(2+)
Q27269230

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Secondary outcomes included the change in the reticulocyte percentage after 2 weeks of treatment, the increase in hemoglobin level after 4 weeks of treatment, the increase in serum ferritin level after 8 weeks of treatment, and adverse events."( The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia: A Randomized Clinical Trial.
Chen, Q; Li, N; Liu, W; Wang, X; Wu, W; Zhang, M; Zhao, G, 2020)		0.56
" There were no significant differences between the 2 groups regarding the rates of adverse events (46 [20."( The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia: A Randomized Clinical Trial.
Chen, Q; Li, N; Liu, W; Wang, X; Wu, W; Zhang, M; Zhao, G, 2020)		0.56

Bioavailability

ExcerptReferenceRelevance
"Hemoglobin-repletion tests in rats, organoleptic studies, and iron-absorption studies in humans were used to search for Fe sources with high bioavailability that could be added to infant cereals as alternatives to the Fe compounds currently used for fortification."( Iron fortification of infant cereals: a proposal for the use of ferrous fumarate or ferrous succinate.
Burri, J; Cook, JD; Furniss, DE; Hurrell, RF; Lynch, SR; Whittaker, P, 1989)		0.28
" Determining the bioavailability of iron products is a challenge, because iron is naturally present in the blood and some tissues."( Comparative bioavailability of ferrous succinate tablet formulations without correction for baseline circadian changes in iron concentration in healthy Chinese male subjects: a single-dose, randomized, 2-period crossover study.
Cao, GY; Hu, X; Jin, PF; Li, KX; Yang, C; Yue, XY, 2011)		0.37
"The aim of the study was to assess the comparative bioavailability of 200-mg of a test (ferrous succinate,100 mg × 2, Hunan Huana Pharmaceutical Co."( Comparative bioavailability of ferrous succinate tablet formulations without correction for baseline circadian changes in iron concentration in healthy Chinese male subjects: a single-dose, randomized, 2-period crossover study.
Cao, GY; Hu, X; Jin, PF; Li, KX; Yang, C; Yue, XY, 2011)		0.37
" The relative bioavailability of the test-reference preparations was 101."( Comparative bioavailability of ferrous succinate tablet formulations without correction for baseline circadian changes in iron concentration in healthy Chinese male subjects: a single-dose, randomized, 2-period crossover study.
Cao, GY; Hu, X; Jin, PF; Li, KX; Yang, C; Yue, XY, 2011)		0.37

Dosage Studied

ExcerptRelevanceReference
" groups in terms of sex, age, duration of hemodialysis, dialysis frequency per week, EPO dosage per week, the level of intact parathyroid hormone, serum creatinine, blood urea nitrogen, or hematological parameters at baseline."( Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li, H; Wang, SX, 2008)		0.35
" The average weekly EPO dosage used was lower in SXN group than in FS group (P<0."( Effect of Sheng Xue Ning Tablets on Renal Anemia in Patients Subject to Maintenance Hemodialysis and Safety Evaluation: A Multi-setting Prospective Randomized Study.
Guo, ZY; Jiang, GR; Ma, J; Mei, CL; Ni, ZH; Rong, S; Tang, XJ; Wang, NS; Yan, HD; Yuan, WJ; ZHang, LM, 2020)		0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (38.10)18.7374
1990's0 (0.00)18.2507
2000's5 (23.81)29.6817
2010's6 (28.57)24.3611
2020's2 (9.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (57.14%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (4.76%)4.05%
Observational0 (0.00%)0.25%
Other8 (38.10%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Efficacy and Safety of Ferrous Iron on the Prevention of Vascular Cognitive Impairment Among Patients With Cerebral Infarction/TIA,FAVORITE [NCT03891277]Phase 21,006 participants (Anticipated)Interventional2019-04-01Recruiting
The Effects of Ferric Derisomaltose on Postoperative Anemia in Patients Undergoing Spinal Deformity Surgery: A Prospective Randomized Controlled Study [NCT05714007]Phase 4120 participants (Anticipated)Interventional2023-08-31Recruiting
The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA) [NCT02631668]Phase 4440 participants (Actual)Interventional2016-01-01Completed
Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g [NCT00558454]Phase 4380 participants (Actual)Interventional2004-03-31Completed
Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation [NCT03010579]Phase 470 participants (Anticipated)Interventional2016-10-31Recruiting
Prospective Study of Iron Deficiency Anemia in Twin Pregnancy [NCT04975074]Phase 41,000 participants (Anticipated)Interventional2021-07-15Not yet recruiting
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study [NCT00964496]Phase 255 participants (Actual)Interventional2004-11-30Completed
A Multicenter, Randomized, Double-blind, Parallel Controlled Clinical Study on the Efficacy and Safety of Compound E Jiao Jiang(cEJJ）in the Treatment of Postpartum Anemia [NCT06175117]Phase 4360 participants (Anticipated)Interventional2023-12-31Not yet recruiting
A Multicenter Randomized Controlled Study of Shengxuening Tablet in the Treatment of Chemotherapy-related Anemia in Hematologic Tumors [NCT05784870]Phase 3168 participants (Anticipated)Interventional2023-02-07Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00964496 (7) [back to overview]Cessation of Bleeding
NCT00964496 (7) [back to overview]Change From Baseline in Bleeding Duration at 12 Months
NCT00964496 (7) [back to overview]Change From Baseline in Bleeding Episodes at 12 Months
NCT00964496 (7) [back to overview]Change From Baseline in Hemoglobin (Hb) Level at 12 Months
NCT00964496 (7) [back to overview]Change From Baseline in Total Transfused Red Cell Requirements at 12 Months
NCT00964496 (7) [back to overview]Participants Dependent on Blood Transfusions
NCT00964496 (7) [back to overview]Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months

Cessation of Bleeding

The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment. (NCT00964496)
Timeframe: 52 months

Interventionparticipants (Number)
Thalidomide Group13
Iron-controlled Group0

[back to top]

Change From Baseline in Bleeding Duration at 12 Months

The change from baseline in bleeding duration at 12 months (NCT00964496)
Timeframe: baseline and 12 months

Interventiondays (Mean)
Thalidomide Group5.2
Iron-controlled Group0.8

[back to top]

Change From Baseline in Bleeding Episodes at 12 Months

The Change from baseline in bleeding episodes at 12 months (NCT00964496)
Timeframe: baseline and 12 months

Interventionbleeding episodes (Mean)
Thalidomide Group-9.36
Iron-controlled Group1.41

[back to top]

Change From Baseline in Hemoglobin (Hb) Level at 12 Months

The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months. (NCT00964496)
Timeframe: baseline and 12 months

Interventiong/L (Mean)
Thalidomide Group3.06
Iron-controlled Group-0.01

[back to top]

Change From Baseline in Total Transfused Red Cell Requirements at 12 Months

Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients (NCT00964496)
Timeframe: baseline and 12 months

Interventionmilliliter (Mean)
Thalidomide Group-1585.71
Iron-controlled Group-28.57

[back to top]

Participants Dependent on Blood Transfusions

Numbers of participants dependent on blood transfusions (NCT00964496)
Timeframe: 52 months

Interventionparticipants (Number)
Thalidomide Group3
Iron-controlled Group13

[back to top]

Participants Whose Rebleeds Decreased From Baseline by ≥ 50% at 12 Months

The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. (NCT00964496)
Timeframe: baseline and 12 months

Interventionparticipants (Number)
Thalidomide Group20
Iron-controlled Group1

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
metronidazole
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.		3.4211C-nitro compound;
imidazoles;
primary alcohol		antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic
oxotremorine
Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.		2.0510N-alkylpyrrolidine
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		3.3511ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
galantamine
Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.		2.0510benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound		antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite
d-alpha tocopherol
Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.		1.9510alpha-tocopherolalgal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite
ferrous sulfate
ferrous sulfate: Ferro-Gradumet is ferrous sulfate in controlled release form; RN given refers to Fe(+2)[1:1] salt. iron(2+) sulfate (anhydrous) : A compound of iron and sulfate in which the ratio of iron(2+) to sulfate ions is 1:1. Various hydrates occur naturally - most commonly the heptahydrate, which loses water to form the tetrahydrate at 57degreeC and the monohydrate at 65degreeC.		2.3920iron molecular entity;
metal sulfate		reducing agent
transferrin
Transferrin: An iron-binding beta1-globulin that is synthesized in the LIVER and secreted into the blood. It plays a central role in the transport of IRON throughout the circulation. A variety of transferrin isoforms exist in humans, including some that are considered markers for specific disease states.		4.3611
glucaric acid
Glucaric Acid: A sugar acid derived from D-glucose in which both the aldehydic carbon atom and the carbon atom bearing the primary hydroxyl group are oxidized to carboxylic acid groups.. D-glucaric acid : The D-enantiomer of glucaric acid.. glucaric acid : A hexaric acid derived by oxidation of sugar such as glucose with nitric acid.		5.3122glucaric acidantineoplastic agent
amoxicillin
Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.		3.4211penicillin allergen;
penicillin		antibacterial drug
fe(iii)-edta
Fe(III)-EDTA: iron fortifying agent; RN given refers to parent cpd		3.3511iron coordination entity
ferrous fumarate
ferrous fumarate: used in treatment of iron deficiency anemia; RN given refers to Fe(+2)[1:1] salt		8.3611dicarboxylic acid
bismuth tripotassium dicitrate
bismuth tripotassium dicitrate: contains tripotassium di-citratobismuthate used in gastric & duodenal ulcer therapy; do not confuse with colloidal bismuth subnitrate		3.4211
losartan potassium
Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.		4.3411
ascorbic acid
Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.		4.5511ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent
ferric oxide, saccharated
Ferric Oxide, Saccharated: A glucaric acid-iron conjugate that is used in the treatment of IRON-DEFICIENCY ANEMIA, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical.		5.3122
ConditionIndicatedRelationship StrengthStudiesTrials
Chronic Kidney Failure
[description not available]		05.3622
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		06.87103
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		05.3622
Anemias, Iron-Deficiency
[description not available]		07.4284
Anemia, Iron-Deficiency
Anemia characterized by decreased or absent iron stores, low serum iron concentration, low transferrin saturation, and low hemoglobin concentration or hematocrit value. The erythrocytes are hypochromic and microcytic and the iron binding capacity is increased.		07.4284
Age-Related Memory Disorders
[description not available]		02.4320
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		02.4320
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.6730
Injuries, Radiation
[description not available]		02.0510
Acute Disease
Disease having a short and relatively severe course.		02.0510
Anemia, Hypochromic
Anemia characterized by a decrease in the ratio of the weight of hemoglobin to the volume of the erythrocyte, i.e., the mean corpuscular hemoglobin concentration is less than normal. The individual cells contain less hemoglobin than they could have under optimal conditions. Hypochromic anemia may be caused by iron deficiency from a low iron intake, diminished iron absorption, or excessive iron loss. It can also be caused by infections or other diseases, therapeutic drugs, lead poisoning, and other conditions. (Stedman, 25th ed; from Miale, Laboratory Medicine: Hematology, 6th ed, p393)		04.5761
Complications, Pregnancy
[description not available]		01.9310
Chronic Illness
[description not available]		03.4211
Infections, Helicobacter
[description not available]		03.4211
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		03.4211
Gastritis
Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.		03.4211
Helicobacter Infections
Infections with organisms of the genus HELICOBACTER, particularly, in humans, HELICOBACTER PYLORI. The clinical manifestations are focused in the stomach, usually the gastric mucosa and antrum, and the upper duodenum. This infection plays a major role in the pathogenesis of type B gastritis and peptic ulcer disease.		03.4211
Abdominal Cramps
[description not available]		03.3511
Colonic Inertia
Symptom characterized by the passage of stool once a week or less.		03.3511
Infantile Diarrhea
[description not available]		03.3511
Constipation
Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections.		03.3511
Diarrhea, Infantile
DIARRHEA occurring in infants from newborn to 24-months old.		03.3511
Complication, Postoperative
[description not available]		03.3411
Postoperative Complications
Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery.		03.3411
Bradykinesia
[description not available]		0210
Hyperactivity, Motor
[description not available]		0210
Iron Overload
An excessive accumulation of iron in the body due to a greater than normal absorption of iron from the gastrointestinal tract or from parenteral injection. This may arise from idiopathic hemochromatosis, excessive iron intake, chronic alcoholism, certain types of refractory anemia, or transfusional hemosiderosis. (From Churchill's Illustrated Medical Dictionary, 1989)		0210
Infant, Premature, Diseases
Diseases that occur in PREMATURE INFANTS.		01.9710
Anemia, Hemolytic, Acquired
[description not available]		01.9710
Icterus Gravis Neonatorum
[description not available]		01.9710
Anemia, Hemolytic
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).		01.9710
Jaundice, Neonatal
Yellow discoloration of the SKIN; MUCOUS MEMBRANE; and SCLERA in the NEWBORN. It is a sign of NEONATAL HYPERBILIRUBINEMIA. Most cases are transient self-limiting (PHYSIOLOGICAL NEONATAL JAUNDICE) occurring in the first week of life, but some can be a sign of pathological disorders, particularly LIVER DISEASES.		01.9710